# US 2021/0277489 A1 · METHODS AND REAGENTS FOR THE SPECIFIC AND SENSITIVE DETECTION OF SARS-CoV-2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277489 A1
- Document ID: US20210277489A1
- Status: Published application
- Kind: A1
- Application number: 17/210,637
- Filed: 2021-03-24
- Published: 2021-09-09
- Earliest claimed: 2020-03-05
- Assignees: Institut Paster
- Applicants: Institut Paster
- Inventors: Flora DONATI; Mélanie ALBERT; Sylvie BEHILLIL; Vincent ENOUF; Sylvie van der WERF
- Web page: https://patentgrep.com/patent/US20210277489A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/701: {Specific hybridization probes}
- C12N 15/1096: {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods, primers, sets of primers, probes, compositions, and kits for detecting presence or absence of SARS-CoV-2 in a sample are provided.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A method for specific detection of the presence or absence of a SARS-CoV-2 RNA in a sample, comprising:
providing a sample; and
subjecting the sample to a reverse transcription reaction with a reverse primer to generate a cDNA copy of SARS-CoV-2 RNA in the sample, amplifying any resultant cDNA, and detecting any amplified product with a probe,
wherein the reverse primer comprises the sequence 5′-CTGGTCAAGGTTAATATAGG-3′ (SEQ ID NO: 5) or a variant thereof, and is from 17 to 23 bases in length; and/or
wherein the forward primer comprises the sequence 5′-GGTAACTGGTATGATTTCG-3′ (SEQ ID NO: 4), or a variant thereof, and is from 16 to 22 bases in length; and/or
wherein the probe comprises the sequence 5′-TCATACAAACCACGCCAGG-3′ (SEQ ID NO: 6), or a variant thereof, or the complement of either of these, and is from 16 to 22 bases in length.

### Claim 37 (depends on 36)

The method of claim 36,
wherein the reverse primer consists of the sequence 5′-CTGGTCAAGGTTAATATAGG-3′ (SEQ ID NO: 5); and/or
wherein the forward primer consists of the sequence 5′-GGTAACTGGTATGATTTCG-3′ (SEQ ID NO: 4); and/or
wherein the probe consists of the sequence 5′-TCATACAAACCACGCCAGG-3′ (SEQ ID NO: 6), or the complement thereof.

### Claim 38 (depends on 37)

The method of claim 37,
wherein the reverse primer consists of the sequence 5′-CTGGTCAAGGTTAATATAGG-3′ (SEQ ID NO: 5);
wherein the forward primer consists of the sequence 5′-GGTAACTGGTATGATTTCG-3′ (SEQ ID NO: 4); and
wherein the probe consists of the sequence 5′-TCATACAAACCACGCCAGG-3′ (SEQ ID NO: 6), or the complement thereof.

### Claim 39 (depends on 36)

The method of claim 36, wherein the presence of the amplified product is detected.

### Claim 40 (depends on 36)

The method of claim 36, wherein the absence of the amplified product is detected.

### Claim 41 (depends on 36)

The method of any of claim 36, wherein the method is an RT-PCR method.

### Claim 42 (depends on 36)

The method of any of claim 36, wherein the method comprises reverse transcribing and amplifying an internal positive control, and detecting an amplified internal positive control product with a probe.

### Claim 43 (depends on 42)

The method of claim 42,
wherein the reverse transcribing and amplifying is performed using an internal positive control reverse primer comprising the sequence 5′-ATATTGCAGCAGTACGCACACA-3′ (SEQ ID NO: 8), or a variant thereof, that is from 19 to 25 bases in length; and/or
an internal positive control forward primer comprising the sequence 5′-ACAGGTACGTTAATAGTTAATAGCGT-3′ (SEQ ID NO: 7), or a variant thereof, that is from 23 to 29 bases in length; and/or
an internal positive control probe comprising the sequence 5′-ACACTAGCCATCCTTACTGCGCTTCG-3′ (SEQ ID NO: 9), or the complement thereof, that is from 23 to 29 bases in length.

### Claim 44 (depends on 43)

The method of any of claim 43, wherein the probe and the internal positive control probe are labelled with 6-carboxy-fluorescein (6FAM) or hexachloro-6-carboxy-fluorescein (HEX) at the 5′ end.

### Claim 45 (depends on 43)

The method of any of claim 43, wherein the probe and the internal positive control probe are labelled with black hole quencher 1 (BHQ1) at the 3′ end.
